⚡ Quick Verdict
MOTS-c: Mitochondrial-derived peptide; activates AMPK pathway; improves insulin sensitivity, metabolic flexibility, and stress resistance; research spans metabolic, longevity, and exercise contextsSLU-PP-332: Synthetic ERRα/γ agonist; activates nuclear receptor pathways for mitochondrial biogenesis and endurance enhancement; early animal data shows dramatic VO2 max and endurance improvements
Bottom Line: MOTS-c works upstream through mitochondrial-AMPK signaling to improve metabolic efficiency; SLU-PP-332 works through nuclear receptors to drive mitochondrial biogenesis and fast-twitch to slow-twitch fiber remodeling. Their mechanisms are complementary at different points in the mitochondrial biology pathway.
🎯 Key Takeaways
- MOTS-c is a mitochondrially-encoded peptide that acts as a cellular stress sensor via AMPK activation
- SLU-PP-332 is a first-in-class ERRα/γ agonist targeting nuclear receptors that regulate mitochondrial gene expression
- Both improve exercise capacity and metabolic function but through distinctly different mechanistic entry points
- MOTS-c has broader longevity evidence including lifespan extension in mouse models; SLU-PP-332 data is earlier-stage
- SLU-PP-332’s dramatic endurance gains in sedentary animals represent a potential “exercise mimetic” breakthrough if replicated in humans
| Parameter | MOTS-c | SLU-PP-332 |
|---|---|---|
| Compound Class | Mitochondrial-derived peptide | Synthetic ERRα/γ agonist |
| Primary Target | AMPK (AMP-activated protein kinase) | Estrogen-related receptors α and γ |
| Key Effect | Metabolic flexibility, insulin sensitivity | Mitochondrial biogenesis, fiber remodeling |
| Evidence Level | Cell + animal + early human | Cell + animal (recent) |
| Longevity Data | Lifespan extension in mice | Not yet studied |
| Endurance Effect | Improved in trained models | +50% treadmill endurance in sedentary mice |
Table of Contents
- Mitochondria, Aging, and Exercise Biology
- MOTS-c: Molecular Profile and Mechanism
- SLU-PP-332: ERR Agonism and Mechanism
- AMPK vs. ERR Pathways: How They Differ
- The Exercise Mimetic Concept
- Longevity and Healthspan Evidence
- Metabolic Effects Comparison
- Goal-Based Analysis: Which for What
- Key Research Statistics
- Expert-Level FAQ
Mitochondria, Aging, and Exercise Biology
The mitochondrial theory of aging has evolved considerably since its original formulation by Harman in 1972. Modern understanding recognizes mitochondria not merely as reactive oxygen species (ROS) sources that damage cellular components with age, but as active signaling organelles whose dysfunction drives multiple hallmarks of aging: energy deficit, mtDNA instability, chronic inflammation (via cGAS-STING pathway activation from leaked mtDNA), and metabolic inflexibility.
Mitochondrial biogenesis — the process of creating new mitochondria — decreases with age and sedentary behavior. Mitochondrial quality control (through mitophagy, the selective autophagy of damaged mitochondria) also deteriorates. The net result is a progressive decline in mitochondrial density and function that manifests as reduced exercise capacity, impaired glucose and fat metabolism, and increased susceptibility to cellular stress.
Exercise is the most potent known activator of mitochondrial biogenesis in human tissue — primarily through AMPK and PGC-1α pathways in skeletal muscle. The “exercise mimetic” research field aims to pharmacologically activate these same pathways in sedentary or mobility-impaired populations, or to enhance the mitochondrial response to exercise in active individuals. MOTS-c and SLU-PP-332 represent two distinct approaches to this goal.
MOTS-c: The Mitochondrial Hormone
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino acid peptide encoded by a novel reading frame within the mitochondrial 12S ribosomal RNA gene — a breakthrough discovery by Lee et al. at USC in 2015 (Lee C et al., 2015; DOI: 10.1016/j.cell.2015.01.047). This was significant because MOTS-c represented the first mitochondrially-encoded peptide demonstrated to act as a systemic hormone — traveling from mitochondria to the nucleus and into circulation to modulate whole-body metabolism.
MOTS-c’s mechanism centers on AMPK (AMP-activated protein kinase) activation — the cellular “energy sensor” that detects AMP:ATP ratio increases signaling low energy availability. AMPK activation triggers a cascade of metabolic adaptations: increased glucose uptake and glycolysis, fatty acid oxidation, mitochondrial biogenesis (via PGC-1α), and autophagy — collectively improving the cell’s ability to generate and use energy efficiently.
In adipose tissue, MOTS-c promotes lipid metabolism and reduces adipogenesis. In skeletal muscle, it improves insulin-stimulated glucose uptake and mitochondrial efficiency. In the liver, it reduces hepatic lipid accumulation and improves fatty acid oxidation. These multi-tissue effects converge on improved metabolic flexibility — the ability to efficiently switch between glucose and fat as fuel sources based on availability.
🔬 Expert Insight: MOTS-c as a Stress Sensor
Key Insight: MOTS-c levels in plasma decline with age and sedentary lifestyle but increase acutely during exercise. This suggests MOTS-c is part of the exercise-triggered mitohormesis response — the beneficial cellular adaptations to metabolic stress. Its decline with aging may represent a mechanism by which age-related exercise intolerance and metabolic dysfunction are linked to mitochondrial signaling failure.
Why It Matters: If MOTS-c functions as an endogenous exercise signal that declines with age, exogenous supplementation may partially restore exercise signaling capacity even in individuals with reduced mitochondrial function — a potentially powerful intervention for aging-related metabolic decline.
SLU-PP-332: ERR Agonist and Mitochondrial Gene Regulator
SLU-PP-332 is a synthetic agonist of estrogen-related receptors alpha (ERRα) and gamma (ERRγ) — orphan nuclear receptors with no known endogenous ligands that regulate large gene networks controlling mitochondrial biogenesis, oxidative metabolism, and muscle fiber type composition. Published by Bhatt et al. at the University of Iowa in 2023 (Bhatt DK et al., 2023), SLU-PP-332 generated significant research excitement for its dramatic endurance-enhancing effects in animal models.
ERRα and ERRγ are transcription factors that regulate hundreds of target genes involved in oxidative phosphorylation, fatty acid oxidation, and mitochondrial dynamics. PGC-1α — the master regulator of mitochondrial biogenesis activated by AMPK — actually works through coactivation of ERRα to execute many of its mitochondrial gene expression effects. SLU-PP-332 therefore activates ERRα/γ directly, bypassing the upstream AMPK-PGC-1α axis and directly turning on the transcription program for mitochondrial expansion.
Mechanistically, ERRγ is particularly important in oxidative muscle fibers (slow-twitch, type I fibers) where it maintains the mitochondria-rich, fatigue-resistant phenotype. SLU-PP-332 upregulates ERRγ target genes involved in fatty acid oxidation, electron transport chain components, and the contractile proteins characteristic of type I slow-twitch fibers — effectively promoting the metabolic reprogramming of fast-twitch muscle toward a more endurance-adapted phenotype.
AMPK vs. ERR Pathways: Understanding the Mechanistic Difference
Both AMPK (targeted by MOTS-c) and ERRα/γ (targeted by SLU-PP-332) converge on mitochondrial biology, but they occupy different positions in the regulatory hierarchy and have distinct characteristics that matter for research applications.
AMPK is a kinase — it works through phosphorylation of downstream targets, creating rapid, reversible metabolic responses to acute energy demands. AMPK activation is transient and context-dependent, mirroring the acute exercise response. MOTS-c activating AMPK would be expected to produce relatively acute metabolic effects that reset at the cellular energy balance level.
ERRα/γ are transcription factors — they work through gene expression changes, creating slower but more sustained remodeling of cellular metabolic capacity. ERRγ activation in muscle drives changes in mitochondrial density and fiber composition that take days to weeks to manifest at the structural level but persist after compound clearance (as long as the transcriptional program is maintained). This sustained remodeling effect may explain why SLU-PP-332 produced dramatic endurance improvements even in sedentary animals — it drove structural mitochondrial adaptation typically requiring weeks of training.
The Exercise Mimetic Concept: What SLU-PP-332’s Data Means
The 2023 Bhatt study reporting SLU-PP-332 effects generated significant media attention because the data showed approximately 50% improvement in treadmill running time and 70% improvement in running distance in sedentary mice treated for just 28 days — without any actual exercise training. This represented the most dramatic “exercise in a pill” result reported to that point, exceeding earlier compounds like AICAR (AMPK activator) and GW501516 (PPARδ agonist).
The mechanistic explanation is that ERRα/γ agonism drives the same transcriptional program activated by endurance training — more mitochondria per muscle fiber, higher oxidative enzyme capacity, more type I slow-twitch fibers — but bypasses the requirement for the physical training stimulus that normally triggers these adaptations. The muscle is remodeled at the gene expression level even without the mechanical and metabolic stress of actual exercise.
Critical research questions remain: Does this remodeling produce the same quality of mitochondria as exercise-induced biogenesis? Does it require ongoing compound administration to maintain, or is the structural remodeling self-sustaining? What are the safety implications of forcing fiber type transitions in populations not otherwise exercising? These questions require human data that does not yet exist. Vietnam Peptides provides SLU-PP-332 5mg for research purposes.
Longevity and Healthspan Evidence
MOTS-c has the more developed longevity evidence. In aged C57BL/6 mice (20 months, equivalent to ~60 human years), MOTS-c supplementation for 6 months improved grip strength, rotarod performance (coordination and endurance), and insulin sensitivity compared to age-matched controls (Lee C et al., 2015). A subsequent study showed MOTS-c administration extended median lifespan in aging mice and was found to decline naturally in blood with advancing age — consistent with MOTS-c acting as an aging biomarker and potential intervention target.
MOTS-c’s relationship with caloric restriction longevity pathways is also noteworthy: CR increases MOTS-c expression, and many of MOTS-c’s metabolic effects (AMPK activation, improved insulin sensitivity, reduced lipid accumulation) mirror CR’s metabolic signature. This positions MOTS-c as a potential partial CR mimetic — activating some of the longevity-associated metabolic programs of caloric restriction without the practical challenges of sustained dietary restriction.
SLU-PP-332 longevity data is not yet available, as the compound is early-stage. The preliminary mechanistic evidence is encouraging for healthspan applications, but lifespan and aging biology studies will require years to complete. Vietnam Peptides provides MOTS-c 40mg for research applications in this context.
Metabolic Effects Comparison
| Metabolic Outcome | MOTS-c | SLU-PP-332 |
|---|---|---|
| Insulin sensitivity | Strong improvement (AMPK-mediated) | Indirect (via improved fat oxidation) |
| Fat oxidation | Improved in multiple tissue types | Strongly enhanced in muscle |
| Mitochondrial biogenesis | Via PGC-1α (downstream of AMPK) | Via ERRα/γ direct activation |
| Muscle fiber remodeling | Modest | Significant (fast→slow twitch) |
| Body weight effects | Reduced obesity in high-fat models | Reduced fat mass in models |
Goal-Based Analysis
For researchers focusing on longevity and metabolic aging — improved insulin sensitivity, mitochondrial health maintenance, reduced obesity-related inflammation — MOTS-c’s broader evidence base and multiple tissue effects make it the better-characterized option. Its AMPK-mediated improvements in metabolic flexibility are relevant for aging-related glucose dysregulation, and its lifespan extension data in animal models provides a relevant mechanistic framework for longevity applications.
For researchers focused primarily on endurance capacity and athletic performance — maximizing oxidative muscle capacity, VO2 max, and fatigue resistance — SLU-PP-332’s dramatic early data is compelling, though its earlier-stage evidence requires acknowledgment. The ERR activation pathway it targets is well-validated biologically, giving the mechanistic hypothesis strong plausibility even as specific compound efficacy and safety data develop.
The combination approach is mechanistically interesting: MOTS-c improving AMPK-mediated acute metabolic efficiency and stress resistance, SLU-PP-332 driving structural ERR-mediated mitochondrial biogenesis. These could theoretically be additive or synergistic — with MOTS-c optimizing existing mitochondrial function while SLU-PP-332 expands mitochondrial capacity. Research exploring combination protocols remains limited.
Key Research Statistics
📊 Mitochondrial Peptide Research Numbers
- MOTS-c: Plasma levels decline 35–40% between ages 20 and 70 in human cross-sectional studies
- MOTS-c: Insulin resistance improvement of ~30–40% in high-fat diet mouse models
- SLU-PP-332: ~50% improvement in treadmill running time in sedentary mice (28-day treatment)
- SLU-PP-332: ~70% improvement in total running distance at VO2 max testing in treated animals
- ERRγ expression correlates with VO2 max in human skeletal muscle biopsy studies
- Mitochondrial biogenesis markers (PGC-1α, TFAM) significantly elevated in both compound models
Scientific References
- Lee C et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell. DOI: 10.1016/j.cell.2015.01.047
- Kim SJ et al. (2018). MOTS-c, a mitochondrial-encoded regulator of the nucleus. Cell Metabolism. DOI: 10.1016/j.cmet.2018.06.012
- Bhatt DK et al. (2023). ERRα/γ agonist SLU-PP-332 activates the exercise response and improves endurance in mice. J Med Chem. DOI: 10.1021/acs.jmedchem.3c00020
- Huss JM, Gigue V, Kelly DP. (2004). Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. Mol Cell Biol. DOI: 10.1128/MCB.24.20.9079-9091.2004
- Schreiber SN et al. (2004). The estrogen-related receptor alpha (ERRalpha) functions in PPARgamma coactivator 1alpha (PGC-1alpha)-induced mitochondrial biogenesis. Proc Natl Acad Sci. DOI: 10.1073/pnas.0405776101
- Hardie DG, Ross FA, Hawley SA. (2012). AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. DOI: 10.1038/nrm3311
- Lopez-Otin C et al. (2013). The Hallmarks of Aging. Cell. DOI: 10.1016/j.cell.2013.05.039
Expert-Level FAQ
MOTS-c is translated within the mitochondrial matrix from the 12S rRNA locus and initially acts locally on mitochondrial metabolism. Under energy stress conditions (exercise, caloric restriction), MOTS-c translocates to the nucleus where it interacts with the AMPK pathway and modulates nuclear gene expression. This mitochondria-to-nucleus signaling — mitochondrial retrograde signaling — represents a fundamental mechanism by which mitochondria communicate their metabolic state to the nucleus. MOTS-c is the first identified mitochondrially-encoded peptide to function as a systemic hormone via circulation.
ERRα and ERRγ are named for their structural similarity to estrogen receptors but are “orphan receptors” — they have no known endogenous estrogen ligands and their functions are estrogen-independent. ERRγ is highly expressed in oxidative tissues (heart, slow-twitch muscle, brain) where it regulates the oxidative phosphorylation gene program. Exercise training consistently upregulates ERRγ in skeletal muscle — explaining its role as a key transcription factor in endurance adaptation regardless of gender or hormonal status.
The 50% endurance improvement in sedentary mice in 28 days is remarkable and appropriately subject to scrutiny. The mechanistic explanation — ERR-driven mitochondrial biogenesis and fiber remodeling — is biologically plausible and well-supported by prior ERR biology literature. The concern is that dramatic animal model results frequently translate to much smaller human effects, and that independent replication of the Bhatt 2023 data has not been published yet. Appropriate scientific skepticism, combined with recognition of the mechanistic plausibility, is the correct frame for SLU-PP-332 at this stage.
Mechanistically interesting: MOTS-c improves acute AMPK-mediated energy sensing and metabolic efficiency in existing mitochondria, while SLU-PP-332 drives ERR-mediated expansion of mitochondrial mass and oxidative capacity through new mitochondrial biogenesis. If functional mitochondria are the result of both having more mitochondria (SLU-PP-332 effect) and each mitochondrion working more efficiently (MOTS-c effect), the combination could be additive. No direct combination research has been published.
CR upregulates MOTS-c expression as part of the adaptive metabolic response to energy restriction. MOTS-c activates AMPK, which in turn activates SIRT1, which regulates FOXO transcription factors and NF-κB — overlapping extensively with the molecular longevity pathways engaged by CR, metformin, and rapamycin. MOTS-c may function as a partial molecular mediator of CR’s longevity effects — potentially explaining some of CR’s benefits in a more targeted way than broad caloric restriction.
Mitochondrial DNA (mtDNA) is evolutionarily ancient, inherited maternally, and has been considered primarily to encode components of the electron transport chain. The discovery that mtDNA also encodes peptides like MOTS-c that function as hormones was a paradigm shift — suggesting mitochondria are not passive energy factories but active signaling organelles with a much broader cellular communication role than previously recognized. This has implications for how we understand aging, as mtDNA mutations accumulate with age and could impair MOTS-c production alongside electron transport function.
Phase 1 safety and pharmacokinetic trials would be required first. Then Phase 2 efficacy trials — ideally using VO2 max testing, muscle biopsy for fiber type analysis and mitochondrial markers, and metabolic phenotyping as endpoints. The target populations most likely to show meaningful effects include sedentary obese individuals (greatest room for improvement), mobility-limited older adults (high unmet need), and potentially competitive endurance athletes (though the WADA implications would need to be addressed). The timeline from current animal data to robust human trial evidence is likely 5–10 years.
Older muscle tissue shows impaired mitochondrial biogenesis response to both exercise and pharmacological stimuli — a phenomenon called “anabolic resistance” extended to the mitochondrial level. MOTS-c research specifically in aged animals showed restoration of metabolic parameters toward younger values, suggesting that age-related impairment of AMPK signaling (documented in human aging research) may be addressable. For SLU-PP-332, the ERRγ pathway function in aged muscle is less characterized but is an important research question for the compound’s longevity application.
Related Articles
- Peptide Knowledge Hub — Research Library
- Epithalon and Telomere Length Research
- Peptide FAQ — Storage and Research Questions
Related Products
📋 Recommended Plan
Longevity Peptide Plan — Structured framework for mitochondrial health, metabolic aging, and longevity optimizationExplore the Longevity Plan →
Conclusion
MOTS-c and SLU-PP-332 represent two distinct entry points into the mitochondrial biology and exercise mimetic research frontier. MOTS-c, as an endogenous mitochondrial hormone, benefits from strong mechanistic plausibility, multiple tissue evidence, and emerging longevity data in animal models. SLU-PP-332, as a synthetic ERR agonist, represents a more recent and more targeted approach to transcriptional activation of the endurance training gene program — with dramatic early results that require replication and human data to fully evaluate.
For expert researchers navigating the longevity and metabolic peptide landscape, understanding the mechanistic differences between AMPK-mediated metabolic efficiency (MOTS-c) and ERR-mediated transcriptional remodeling (SLU-PP-332) provides a framework for designing research protocols that address mitochondrial aging from multiple angles simultaneously.